NanoEcho’s core values
Through responsibility, commitment, focus, and reliable delivery, we create value.
These core values not only represent our principles but also our commitment and endeavor to live up to them in every task we undertake. Our goal is to let these values guide us in all our tasks.
Responsibility: We take responsibility for our commitments and tackle challenges with determination. We take ownership and deliver as promised. We speak truthfully and, when uncertain, offer clarity by presenting facts. Through openness, we build trust.
Commitment: With a burning passion for our customers and our mission, we have strong faith in our solution, our product, and our capabilities. We engage collaboratively with customers, colleagues, owners, suppliers, and stakeholders. Together, we strive to meet high expectations.
Focus: With courage and determination, we steer towards our goal. By daring to prioritize, we create value for our customers. We remain focused on fulfilling our customers’ needs.
Delivery: We work to create value, to deliver to our customers, and to keep our promises. Through knowledge, innovation, and collaboration, we ensure quality-driven deliveries.
Management and board
The management consists of people with solid experience and knowledge in medical technology and commercialization. There is also a background of successfully driving products from idea stage to successful launches
Board of directors
Björn Larsson
Acting CEO since 2026
Holdings: 4 000 000 warrants through incentive program (via Smarter Industry AB)
E-mail: bl@nanoecho.se
Background: Björn Larsson has an MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Bjorn has also been investment manager Life science for GU Ventures.
Other Current Assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
CTO since 2026
Holdings: –
E-mail: nl@nanoecho.se
Background: Nils Löfgren holds a PhD in signal processing from Chalmers University of Technology. He has over 20 years’ experience in senior leadership roles within the development and industrialisation of advanced medical technology systems, across both start-ups and growth companies in the life sciences sector. He has extensive expertise in areas including ultrasound, signal processing, software development, as well as clinical, regulatory and commercial processes. He has previously worked at, among others, Neoventa Medical, Cubist IT and Nanolyze.
Other Current Assignments: –
Dr. Ulrika Axelsson
Clinical Director since 2023
Holdings: 104 759 shares and 562 500 warrants through incentive program
Background: Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
Other Current Assignments: –
Björn Larsson
Acting CEO since 2026
Holdings: 4 000 000 warrants through incentive program (via Smarter Industry AB)
E-mail: bl@nanoecho.se
Background: Björn Larsson has an MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Bjorn has also been investment manager Life science for GU Ventures.
Current assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
Nils Löfgren
CTO since 2026
Holdings: –
E-mail: nl@nanoecho.se
Background: Nils Löfgren holds a PhD in signal processing from Chalmers University of Technology. He has over 20 years’ experience in senior leadership roles within the development and industrialisation of advanced medical technology systems, across both start-ups and growth companies in the life sciences sector. He has extensive expertise in areas including ultrasound, signal processing, software development, as well as clinical, regulatory and commercial processes. He has previously worked at, among others, Neoventa Medical, Cubist IT and Nanolyze.
Other Current Assignments: –
Dr. Ulrika Axelsson
Clinical Director since 2020
Holdings: 104 759 shares and 562 500 warrants through incentive program
Background: Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
Other Current Assignments: –
Management team
Micael Wikberg
Chairman of the Board since 2026
Holdings: 31,010,746 shares (through Günther & Wikberg Kapitalförvaltning AB, Günther & Wikberg Holding AB, and ATH Invest AB)
Education and Background: Master of Science in Business and Economics from the Stockholm School of Economics. Micael has extensive experience from senior positions within the Swedish capital markets and financial sector, with a broad background in banking, securities brokerage, and asset management. He has previously served as Deputy Chief Executive Officer and Head of Securities Brokerage at Föreningsbanken, as well as Chief Executive Officer of Matteus AB and Matteus Fondkommission AB.
Other Current Assignments: Founder, Chief Executive Officer, and Founding Partner of Günther & Wikberg Kapitalförvaltning AB. Chairman of the Board of Aqurat Fondkommission AB and Centaur Fondförvaltning AB. In addition, board assignments in Günther & Wikberg Holding AB, Günther & Wikberg Kapitalförvaltning AB, and ATH Invest AB.
Johan Fromholtz
Member of the board since 2026
Holdings: –
Education and Background: Master of Science in Business and Economics from the Stockholm School of Economics. Johan has extensive and broad experience from senior positions within the Swedish capital markets, with a background in banking, securities brokerage, and asset management. He has held senior roles at, among others, Jacobsson & Ponsbach Fondkommission, Invik & Co, and JP Nordiska Fondkommission. Johan also has extensive experience as a corporate finance executive, including serving as Deputy Chief Executive Officer and Senior Partner within the G&W Group.
Other Current Assignments: Senior Advisor and Board Member within the G&W Group. Board assignments in Günther & Wikberg Holding AB and Arelium AB, as well as Board Member and Deputy Chief Executive Officer of Günther & Wikberg Kapitalförvaltning AB.
Björn Larsson
Member of the board since 2025
Holdings: 4 000 000 warrants through incentive program (via Smarter Industry AB)
Education and Background: MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Björn has also been investment manager Life science for GU Ventures.
Other Current Assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
Micael Wikberg
Chairman of the Board since 2026
Holdings: 31,010,746 shares (through Günther & Wikberg Kapitalförvaltning AB, Günther & Wikberg Holding AB, and ATH Invest AB)
Education and Background: Master of Science in Business and Economics from the Stockholm School of Economics.
Micael has extensive experience from senior positions within the Swedish capital markets and financial sector, with a broad background in banking, securities brokerage, and asset management. He has previously served as Deputy Chief Executive Officer and Head of Securities Brokerage at Föreningsbanken, as well as Chief Executive Officer of Matteus AB and Matteus Fondkommission AB.
Other Current Assignments: Founder, Chief Executive Officer, and Founding Partner of Günther & Wikberg Kapitalförvaltning AB. Chairman of the Board of Aqurat Fondkommission AB and Centaur Fondförvaltning AB. In addition, board assignments in Günther & Wikberg Holding AB, Günther & Wikberg Kapitalförvaltning AB, and ATH Invest AB.
Independent in relation to the Company and to major shareholders.
Johan Fromholtz
Board Member since 2026
Holdings: –
Education and Background: Master of Science in Business and Economics from the Stockholm School of Economics. Johan has extensive and broad experience from senior positions within the Swedish capital markets, with a background in banking, securities brokerage, and asset management. He has held senior roles at, among others, Jacobsson & Ponsbach Fondkommission, Invik & Co, and JP Nordiska Fondkommission. Johan also has extensive experience as a corporate finance executive, including serving as Deputy Chief Executive Officer and Senior Partner within the G&W Group.
Other Current Assignments: Senior Advisor and Board Member within the G&W Group. Board assignments in Günther & Wikberg Holding AB and Arelium AB, as well as Board Member and Deputy Chief Executive Officer of Günther & Wikberg Kapitalförvaltning AB.
Independent in relation to the Company and to major shareholders.
Björn Larsson
Member of the board since 2025
Holdings: 4 000 000 warrants through incentive program (via Smarter Industry AB)
Education and Background: MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Bjorn has also been investment manager Life science for GU Ventures.
Current assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.